Evaluation of hs-CRP and IVUS on major adverse cardiac event in patients with after coronary artery intermediate lesions stent implantation
10.3760/cma.j.issn.1008-6706.2012.15.009
- VernacularTitle:高敏C反应蛋白结合血管内超声对冠心病临界病变介入术后心脏不良事件的评价
- Author:
Jun JI
;
Shenghu HE
;
Rixin XU
;
Xiaodong LIU
;
Shu CHEN
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
C-reactive protein;
Coronary angiography
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(15):2258-2260
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of hs-CRP and IVUS on major adverse cardiac event in patients who after coronary artery intermediate lesions stent implantation.Methods 82 patients with clinical diagnosis of coronary heart disease who had a segmental stenosis degree is 40％ ～ 70％ in one major coronary artery on coronary angiography,all of the patients do intravascular ultrasound,patients had minimal lumen area(MLA) of intermediate lesions ≤ 4mm2( the left main coronary artery)or≤ 6mm2( left main coronary artery) who received percutaneous coronary intervention(PCI),and the patients were divided into 2 groups,hs-CRP rise group(≥3mg/L) and hs-CRP normal group(＜3mg/L),compared the rate between the two groups in hospital and follow up periods by typical angina,nonfatal myocardial infarction,cardiac death and target-vessel revascularization and other major adverse cardiac events (MACE).Results The rate on major adverse cardiac event in hs-CRP rise group was significantly higher than the normal group(P ＜0.01 );the restenosis rate in hs-CRP rise group higher than hs-CRP normal group(P ＜0.01 ).Conclusion hs-CRP could predict the rate on major adverse cardiac event in patients with after coronary artery intermediate lesions stent implantation,the patients of hs-CRP rise group should strengthen antiplatelet,anti-inflammatory treatment etc.
